research Improving selective androgen receptor modulator discovery and preclinical evaluation
We need better ways to test and understand SARMs to make safer and more effective treatments.
Search
for
Sort by
Research
180-210 / 1000+ results research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research PSS21 GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA
No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.
research 6ER-014 Evaluation of baricitinib in paediatric patients with alopecia areata
Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.
research Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
research 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
research The efficacy of scalp-cooling system for the prevention of chemotherapy-induced hair loss in metastatic breast cancer patients treated with eribulin
A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.
research Diagnostic Value of VDR in Bone Metastasis and Prognosis of Patients with Breast Cancer and Expression Correlation between Vitamin D Receptor and Hairless Protein
Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
research Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
research Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation
Dihydroartemisinin helps reduce prostate enlargement in rats by stopping the growth of prostate cells.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
research Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer
Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Identification of neprilysin as a potential target of arteannuin using computational drug repositioning
Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
research A Nonredundant Human Protein Chip for Antibody Screening and Serum Profiling
The technology can help diagnose and subtype autoimmune diseases by identifying specific autoantibodies.
research P14 Mycophenolate mofetil in patients with autoimmune hepatitis intolerant to azathioprine
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017
HPV vaccines are generally safe but need further investigation for rare side effects.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Four-year experience with the preferential derivation care model for multidisciplinary care in patients with psoriasis and psoriatic arthritis
The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.
research Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
Deucravacitinib helped a man regrow hair significantly.
research Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor
A new gene mutation causes vitamin D resistance and rickets, treatable with calcium therapy.
research Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
research The use of a retinoid receptor antagonist in a new model to study vitamin A-dependent developmental events.
The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.